Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 70 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years	Guselkumab (Tremfya; CNTO-1959)	Plaque psoriasis	Dermatology	2024	View \| Download
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis	Glycopyrronium bromide cream	Primary axillary hyperhidrosis	Endocrine Nutritional and Metabolic Disorders	2024	View \| Download
Finerenone for treating heart failure	Finerenone (BAY 948862)	Heart failure (HF)	Cardiovascular System	2024	View \| Download
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years	Ferric Maltol (Feraccru; ST-10)	Anaemia , Iron deficiency	Endocrine Nutritional and Metabolic Disorders	2024	View \| Download
Eszopiclone for treating insomnia	Eszopiclone	Insomnia	Neurology	2024	View \| Download
Eplontersen for treating transthyretin amyloid cardiomyopathy	Eplontersen (ION-682884;AKCEA TTR-LRx)	Transthyretin amyloid cardiomyopathy	Cardiovascular System	2024	View \| Download
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma previously treated with at least one line of systemic therapy	Epcoritamab (GEN-3013)	B-cell non-Hodgkin lymphoma	Haematological Cancer and Lymphomas	2024	View \| Download
Elranatamab monotherapy or with daratumumab for previously treated relapsed or refractory multiple myeloma	Daratumumab (Darzalex; JNJ-54767414) , Elranatamab (PF-06863135)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas , Skin Cancer	2024	View \| Download
Durvalumab and enfortumab vedotin with or without tremelimumab for muscle-invasive bladder cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Enfortumab vedotin (ASG-22ME; Padcev) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2024	View \| Download
Dupilumab for treating bullous pemphigoid	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Bullous pemphigoid	Dermatology	2024	View \| Download